I am also impressed with the last 3 announcements. The superbug and antibiotic resistant diagnostic product will without a doubt add to the coming quarter. The approval was fast tracked due to the seriousness of these pathogens and bugs in hospitals so it will be interesting to see what is to come in 2018. This new product suite could add 100% of current quarterly revenue alone if hospitals around Europe pick this new diagnostic method up. Once the STI suite is approved that will also be an interesting addition to revenue. Quiet company but could be a real winner if commercial contracts get picked up and becomes the go to diagnostic method. Patience may be rewarded big time.
GSS Price at posting:
33.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)